Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Guenova
Emmanuella
E
Weber
Hans Oliver
HO
Voykov
Bogmil
B
Metzler
Gisela
G
Mitev
Vanyo
V
Berneburg
Mark
M
Hoetzenecker
Wolfram
W
Röcken
Martin
M
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003925:Diabetic Angiopathies; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005528:Foot / Q000473:pathology; D005534:Foot Diseases / Q000209:etiology / Q000473:pathology*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D010292:Paresthesia / Q000209:etiology; D011758:Pyrroles / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib